Find the right mouse models for B-cell depletion therapies

Test the efficacy and specificity of your B-cell depleting agent with genO-BRGSF-HIS mice

The genO-BRGSF-HIS mouse was used to test the efficacy of several B-cell depleting agents and specific decreases in B cells were observed:

‍

B-cell depletion induced by Rituximab or a B-cell depleting agent in genO-BRGSF-HIS mice

‍

Key features of the genO-BRGSF-HIS mouse:

• Functional human myeloid and lymphoid compartments upon CD34+ HSC-reconstitution
• Dynamic recruitment of immune cells into the TME and activation profile shaped by tumor burden and type
• Reduced number of murine myeloid cells
• Resistance to irradiation
• Highly permissive to PDX and CDX engraftment
• Presence of functional γδ T cells
• Long lifespan and stable immune system engraftment enabling assessment of compounds with large therapeutic window

‍

Analyze the contribution of the Fc region of therapeutic antibodies for B-cell depletion with genO-hFcγR mice

The genO-hFcγR mouse was used to test the efficacy of anti-CD20 human antibodies:

‍

B-cell depletion induced by Fc-engineered anti-CD20 human antibodies in genO-hFcγR mice

‍

‍

Key features:

• Fully functional humanized receptors (FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, FcγRIIIB)
• Human-like expression pattern of hFcγR
• No expression of murine FcγR
• Fully immunocompetent model

‍